(Total Views: 880)
Posted On: 02/28/2022 9:59:10 AM
Post# of 155783
Re: USS JOHNSTON #119286
USS J,
The statistical reporting in these PRs is murky at best. I believe that this was intended to indicate that the number of patients alive 12 months was 980% higher.
Even the following reports were not clear, especially as the data is for a mix of compassionate use and open label trial patients.
Ohm and others had discussed this better than I am able. My understanding is that Leronlimab demonstrated equal efficacy (without the side effects) to trodelvy, but "too many" patients alive to determine overall survival.
Leronlimab has the opportunity to demonstrate markedly superior survival after the passage of these additional six months. Fingers crossed.
The statistical reporting in these PRs is murky at best. I believe that this was intended to indicate that the number of patients alive 12 months was 980% higher.
Even the following reports were not clear, especially as the data is for a mix of compassionate use and open label trial patients.
Ohm and others had discussed this better than I am able. My understanding is that Leronlimab demonstrated equal efficacy (without the side effects) to trodelvy, but "too many" patients alive to determine overall survival.
Leronlimab has the opportunity to demonstrate markedly superior survival after the passage of these additional six months. Fingers crossed.
(8)
(0)
